Research/Projects

RECOVER: Researching COVID to Enhance Recovery

This multi-site study serves as a platform to understand, diagnose, prevent, and treat long COVID and help people who are suffering. This research is funded by the National Institutes of Health (NIH) Researching COVID to Enhance Recovery (RECOVER) Initiative. The Duke Clinical Research Institute (DCRI) is the Clinical Trials Data Coordinating Center. RECOVER-ENERGIZE study is designed to evaluate interventions for exercise intolerance in post-acute sequelae of SARS-COV2 infection. The platform offers two clinical trials, Exercise Intolerance (Personalized Cardiopulmonary Rehabilitation) and Post-Exertional Malaise (Structured Pacing).

Describing epidemiology and outcomes of coronary microvascular dysfunction in patients with chest pain – a Yale ED-CMD study

This is a prospective observational study with a bio-repository evaluating the prevalence, multi-system manifestation and clinical outcomes associated with coronary microvascular dysfunction diagnosed in the emergency department. Our goal is to to elucidate the symptoms, risk factors, clinical features, treatments and prognosis of patients with CMD.

Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) – Yale-METRO (Metropolitan Emergency Trial Network to advance patient Outcomes)

Supported by funding from the National Institutes of Health (NIH), Yale School of Medicine is a leading hub for a network of medical institutions in the northeast, in collaboration with 12 other large hubs across the U.S. The network conducts clinical trials designed to advance the science of emergency care, improving outcomes for patients with neurologic, cardiac, respiratory, hematologic and trauma emergencies.

Investigating Respiratory Viruses in the Acutely Ill (IVY) Network U.S. Centers for Disease Control and Prevention

This multi-state national surveillance project is assessing vaccine effectiveness for influenza, COVID-19, and RSV vaccines. Through a case-controlled study design of hospitalized patients, the project originally aimed to estimate how well flu vaccines work to prevent severe flu illness among intensive care unit (ICU) patients. With the rise of the COVID-19 pandemic the network expanded to assess how well COVID-19 vaccines work to prevent COVID-19 hospitalizations. As of September 2023, with the new RSV vaccine being distributed the network began assessing the RSV vaccine effectiveness among hospitalized adults.

Investigating the relationship between catecholamines, renalase and angiotensin II in the RAAS pathway in COVID-19 patients (Activ3 Subaward)

This project investigated the role of catecholamines as central to the adverse effects of COVID-19 on clinical outcomes and their modulation with angiotensin II and renalase in hospitalized patients enrolled in Angio-NECTAR study. Catecholamines are important in stress responses however, left unchecked can lead to an increase of cytokine production causing the immune system to aggressively respond to infection.

Novel Experimental COVID Therapies Affecting Host Response (NECTAR)

This was a nationwide clinical trial studying new drug therapies to see if they help patients who are in the hospital and have COVID-19 recover. Therapeutic goals for patients hospitalized for COVID-19 included hastening recovery and preventing progression to critical illness, multiorgan failure, or death. The project objective was to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19.

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management (Platinum)

This was a phase 4, multicenter, randomized, double-blinded, placebo-controlled study in adults who presented to the emergency department with hyperkalaemia. In addition to the current standard combination therapy patients received either patiromer or placebo twice within a 24-hour period. Monitoring potassium blood levels and post-baseline potassium related medical interventions to ascertain net clinical benefit (mean difference in number of interventions less change in serum potassium).

High Sensitivity Near Patient Cardiac Troponin (High Note)

This project was a multi-center, prospective, observational study of US adults who presented to the emergency department with signs and symptoms of myocardial infarction (MI). The study assessed a newly developed fluorescent immunoassay from Quidel. Utilizing the TriageTrue® high-sensitivity Troponin I (TriageTrue) test to validate the clinical performance as an aid in the diagnosis of MI and for use in an accelerated diagnostic protocol for the rapid rule-out of MI.